Intensive lipid-lowering strategy

PreclinicalSmall molecule

Intensive lipid-lowering strategy is one of 3 small molecule programs targeting Chronic Coronary Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Coronary SyndromeRecruiting

Chronic Coronary SyndromePreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Chronic Coronary Syndrome

#DrugCompanyPhaseTrials

Adenocard

Astellas

Approved

1 2

Yangxinshi

SSPH Qingdao Growful Pharmacetical Co.,Ltd

Phase 3

2 3

Intensive lipid-lowering strategy

LLiu yong

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

N/ARecruiting

Chronic Coronary Syndrome

NCT06896708

Clinical

Trials by Indication[1]

Chronic Coronary Syndrome1 trial

Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome

Recruiting·LLiu yong·N/A·NCT06896708·766 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intensive lipid-lowering strategy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intensive lipid-lowering strategy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intensive lipid-lowering strategy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Liu yong company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: LLiu yong

Intensive lipid-lowering strategy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Chronic Coronary Syndrome1 trial

References

Drug Info

Quick Facts

Related News